
BMS to develop and market PDL's multiple myeloma antibody
Executive Summary
PDL BioPharma (oncology and immune disease antibodies) has licensed Bristol-Myers Squibb worldwide rights to its Phase I CS1-targeting antibody elotuzumab for multiple myeloma.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Immuno-Oncology
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com